Segmental Vitiligo

In recent times, segmental vitiligo has become increasingly relevant in various contexts. Expert Highlights Updates in Pediatric Vitiligo Care - Medscape. In the clinical opinion of Lawrence F. Eichenfield, MD, pediatric patients with vitiligo would benefit from improved treatments and management strategies.

This perspective suggests that, “There is a tremendous variation in how ... Building on this, ruxolitinib Shows Consistent Results Across Vitiligo Groups - Medscape. Ruxolitinib cream is effective and safe for treating vitiligo across different subgroups of patients, according to phase 3 studies. Vitiligo Linked to Psychiatric Conditions in Black Children.

A study found a significantly higher risk for several psychiatric disorders in Black children with vitiligo. Vitiligo: Combination Therapies and Emerging Treatments - Medscape. For patients with nonsegmental vitiligo who have clinical signs of active disease, the first goal is to stabilize the active disease and stop further spread of depigmentation.

Similarly, jAK Inhibitors for Vitiligo: More Skin Response Over Time. Two JAK inhibitors for non-segmental vitiligo showed better skin clearance in phase 2b trial extensions — ritlecitinib plus twice-weekly doses of UVB light and upadacitinib. Furthermore, what Can Clinicians Do to Treat Patients With Vitiligo?

Segmental vitiligo is rarer, occurring most commonly in children and teenagers, and refers to lesions in a single unilateral area of the body that appear in one single outbreak. JAK Inhibitor Plus nbUVB Boosts Vitiligo Repigmentation - Medscape. Furthermore, adding nbUVB phototherapy to oral ritlecitinib improves facial and total body repigmentation in patients with nonsegmental vitiligo, a study shows. Vitiligo in Children Linked to Higher Hearing Loss - Medscape.

Pediatric vitiligo is associated with higher risks for sensorineural and mixed hearing loss but not with most ocular conditions. Baricitinib Plus Phototherapy Beneficial for Severe Vitiligo. Combining baricitinib with narrowband UVB phototherapy led to significant repigmentation and enhanced quality of life in adults with active vitiligo, in a phase 2 trial.

Another key aspect involves, fDA Approves Topical Ruxolitinib for Nonsegmental Vitiligo. From another angle, the US Food and Drug Administration has approved topical ruxolitinib (Opzelura) for the treatment of nonsegmental vitiligo in patients aged 12 years or older, the manufacturer, Incyte, announced ...